Close Menu
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Advertisement
X (Twitter) LinkedIn Facebook
X (Twitter) LinkedIn Facebook YouTube
OncologyTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
Subscribe
OncologyTube
[the_ad id="32629"]
Home » Page 12

Oncoceutics Expands IP Portfolio With Additional Patents for ONC201 and ONC212

Brain 2 Mins Read

Philadelphia, PA (October 12, 2020) – Oncoceutics, Inc. announced that the European Patent Office has issued a Decision to Grant…

Andrzej Jakubowiak, MD, Ph.D. @UCCancerCenter #ASCO20 #multiplemyeloma Update of the phase 1/2 EVOLVE study

Multiple Myeloma 3 Mins Read

Andrzej Jakubowiak, MD, Ph.D. of the University of Chicago Comprehensive Cancer Center speaks on the ASCO 2020 abstract Orvacabtagene autoleucel…

Robert Coleman, MD @TheUSONetwork @elevationonc #solidtumors Elevation Oncology and US Oncology Research Announce Collaboration in the Phase 2 CRESTONE Study

Other 2 Mins Read

Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer U.S. Oncology Research discusses Elevation Oncology and US Oncology Research Announce Collaboration…

Paul G. Richardson, MD @DanaFarber #multiplemyeloma First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone

Multiple Myeloma 3 Mins Read

Paul G. Richardson, MD of Dana-Farber Cancer Institute explains the abstract entitled First-in-human phase I study of the novel CELMoD…

Alexander Stratigos, M.D. @uoaofficial #ESMO20 #skincancer #BCC #laBCC Phase II results for cemiplimab in Pts with laBCC

Melanoma Skin Cancer Treatment 2 Mins Read

Alexander Stratigos, M.D., Professor of Dermatology/Or Investigator of the University of Athens Medical School at Andreas Sygros Hospital explains the…

Lung Cancer Video Library Spanish – Raez – TERAPIA DIRIGIDA PARA CANCERES DE PULMON ntrk1 3

Non-Small Cell Lung Cancer 1 Min Read

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…

Lung Cancer Video Library Spanish – Raez TERAPIA DIRIGIDA PARA CANCER DE PULMON – MET Y BRAFV600

Non-Small Cell Lung Cancer 1 Min Read

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…

Lung Cancer Video Library Spanish – Raez – NUEVAS TERAPIAS DIRGIDAS PARA CANCER DE PULMON – RET

Non-Small Cell Lung Cancer 1 Min Read

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…

Lung Cancer Video Library Spanish – Domingo – BIOPSIAS LIQUIDAS Y CANCER DE PULMON

Non-Small Cell Lung Cancer 1 Min Read

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…

Lung Cancer Video Library Spanish – Domingo TERAPIAS – CANCER DE PULMON DE CELULAR PEQUENAS

Non-Small Cell Lung Cancer 1 Min Read

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…

Lung Cancer Video Library Spanish – Domingo – TERAPIA DIRIGIDA PARA CANCER DE PULMON EGFR

Non-Small Cell Lung Cancer 1 Min Read

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…

Lung Cancer Video Library Spanish – Domingo – TERAPIA DIRIGIDA PARA CANCER DE PULMON ALK Y ROS 1

Non-Small Cell Lung Cancer 1 Min Read

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón, producida en español para nuestra comunidad…

Lung Cancer Video Library Spanish – Domingo – NECESIDAD DE DIAGNOSTICO MOLECULAR EN CANCER DE PULMON

Non-Small Cell Lung Cancer 1 Min Read

Para estos videos adicionales a nuestra Biblioteca de videos sobre el cáncer de pulmón producidos en español para nuestra comunidad…

Lung Cancer Video Library Spanish – Raez IMMUNOTERAPIA PARA CANCER DE PULMON DE CELULAS NO PEQUENAS

Non-Small Cell Lung Cancer 1 Min Read

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…

Lung Cancer Video Library Spanish – Raez – DESPISTAJE DE CANCER DE PULMON

Non-Small Cell Lung Cancer 1 Min Read

Para este año, además de nuestra videoteca de cáncer de pulmón producida en español para nuestra comunidad latina, el Dr.…

Blood Cancer Video Library – Brody – Mantle Cell Lymphoma – Outcomes CAR T Cell Therapy Trials

Lymphoma 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…

Blood Cancer Video Library – Ruiz – Blood Cancers – Bone Marrow Transplantation and Other Therapies

Lymphoma 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…

Blood Cancer Video Library – Ruiz – Diagnosis and Management of Blood Cancers

Lymphoma 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…

Blood Cancer Video Library – Ruiz – The Prevalence and Epidemiology of Blood Cancers

Lymphoma 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…

Blood Cancer Video Library – Brody – Chronic Lymphocytic Leukemia (CLL) – New BTK Inhibitors

Chronic Lymphocytic Leukemia 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…

Blood Cancer Video Library – Brody – Bi-specific Antibody – DLBCL & Follicular Lymphoma

Lymphoma 1 Min Read

For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…

Lung Cancer Video Library – Gubens – Targeted Therapies in NSCLC – Treatment Options for Low PDL1

Non-Small Cell Lung Cancer 1 Min Read

For this video Dr.Matthew Gubens discusses targeted therapies in non small cell lung cancer. What are the leading treatment options…

Lung Cancer Video Library – Gubens – Can Immunotherapy Help Frail Patients with Advanced NSCLC

Non-Small Cell Lung Cancer 1 Min Read

For this video Dr.Matthew Gubens discusses non small cell lung cancer, and immunotherapy. For a frail patient with advanced NSCLC,…

Lung Cancer Video Library – Gubens – What is Tumor Mutational Burden in Lung Cancer Management?

Non-Small Cell Lung Cancer 1 Min Read

For this video Dr.Matthew Gubens discusses non small cell lung cancer, and tumor mutational burden. At this time could TMB…

Lung Cancer Video Library – Das – What is the Role of Immunotherapy for Unresectable Stage lll NSCLC

Non-Small Cell Lung Cancer 1 Min Read

For this video Dr. Millie Das discusses Immunotherapy in non small cell lung cancer., and the current role of immunotherapy…

Lung Cancer Video Library – Das – Targeted Therapies NSCLC PDL1 Expression Leading Treatment Options

Non-Small Cell Lung Cancer 1 Min Read

For this series of the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss targeted therapies in…

Lung Cancer Video Library 2019 – Das – Immunotherapy Activity in Malignant Pleural Mesothelioma

Non-Small Cell Lung Cancer 1 Min Read

For the GRACE Lung Cancer Video Library, Dr. Millie Das joined us to discuss Immunotherapy in non small cell lung…

Prof. Jean Bourhis @CHUVLausanne #ESMO20 #headandneckcancer Results of the GORTEC 2015-01 “PembroRad” randomized trial

Head and Neck 3 Mins Read

Prof. Jean Bourhis, Department Head of Radio-Oncology at the University Hospital of Lausanne and Lead Investigator of Centre Hospitalier Universitaire…

Aditya Bardia, MD, MPH @ABhealer108 @MGHCancerCenter @MassGeneralNews @NateraOncology @NateraGenetics #breastcancer A Collaboration for Prospective Randomized Clinical Trial in Early Stag…

Breast Cancer 2 Mins Read

Aditya Bardia, MD, MPH of Massachusetts General Hospital discusses the Natera Announces Collaboration with Massachusetts General Hospital for a Prospective…

Aditya Bardia, MD, MPH @ABhealer108 @DanaFarber #ESMO20 #breastcancer ASCENT: A randomized phase III study of sacituzumab govitecan vs treatment of physician’s choice

Breast Cancer 2 Mins Read

Aditya Bardia, MD, MPH of Dana-Farber Cancer Institute speaks about ESMO 20 ASCENT: A randomized phase III study of sacituzumab…

Andrea B. Apolo, MD @apolo_andrea @NCIResearchCtr @NIH @NIHClin @theNIH #ESMO20 #kidneycancer New First-Line Treatment Option For Metastatic Kidney Cancer, According To Results Of Phase 3…

Kidney 2 Mins Read

Andrea B. Apolo, MD of NIH National Cancer Institute speaks about the ESMO 2020 abstract New First-Line Treatment Option For…

Angel A. Rodriguez, MD @tutorodriguez @NateraOncology @NateraGenetics @MGHCancerCenter #breastcancer Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinica…

Breast Cancer 3 Mins Read

Angel A. Rodriguez, MD, Oncology Medical Director of Natera speaks about Natera Announces Collaboration with Massachusetts General Hospital for a…

Roy S Herbst, MD, Ph.D.@DrRoyHerbstYale @YaleCancer #ESMO20 #NSCLC Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer 2 Mins Read

Roy S Herbst, MD, Ph.D. of the Yale School of Medicine and Yale Cancer Center discusses ESMO 2020 abstract Yale…

Timothy A. Yap, MD @MDanderson #ESMO20 #advancedsolidtumors Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase 1b/2 SEASTAR Study

General 3 Mins Read

Timothy A. Yap, MD of MD Anderson discusses ESMO 2020 Poster: Rucaparib + Sacituzumab Govitecan: Initial Data From the Phase…

Dr. Zeynep Zengin @ZeynepZengin @cityofhope #ESMO20 #mRCC #carcinoma Assessment of Circulating Cell-Free Tumor DNA in 847 Pts with mRCC

General 3 Mins Read

Dr. Zeynep Zengin, post-doctoral fellow at City of Hope discusses the ESMO Virtual Congress 2020: Assessment of Circulating Cell-Free Tumor…

Professor Ray McDermott @RayMcDermott1 @svuh #ESMO20 #genefusion #NTRKgene Survival benefits of larotrectinib in an integrated dataset of Pts with TRK fusion cancer

General 5 Mins Read

Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland discusses ESMO – Survival benefits of larotrectinib in…

Professor Ray McDermott @RayMcDermott1 @svuh #ESMO20 #prostatecancer #ANZUP1801 DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate

Prostate Cancer Treatment 2 Mins Read

Professor Ray McDermott of St. Vincent University Hospital and Tallaght Hospital, Ireland explains the ESMO poster DASL-HiCaP: Darolutamide augments standard…

Peter R. Galle, MD @uni_mainz_eng @uni_mainz #HCC #hepatocellularcarcinoma Updated results of a phase Ib study of REG plus PEMBRO

General 3 Mins Read

Peter R. Galle, MD of University Medical Center Mainz discusses his ESMO 2020 abstract – Updated results of a phase…

W. Michael Korn, MD, CMO @carisls #ESMO20 #ovariancancer Caris Life Sciences to Present New Ovarian Cancer Research at ESMO Virtual Congress 2020

Ovarian 2 Mins Read

W. Michael Korn, MD, CMO of Caris Life Sciences discusses their abstract – Caris Life Sciences Presented New Ovarian Cancer…

Jacob J. Adashek, DO @jacobadashek @MoffittNews @Dr_R_Kurzrock #ESMO20 #carcinomas Personalized molecularly matched therapies for carcinomas of unknown primary

General 3 Mins Read

Jacob J. Adashek, DO of the Moffitt Cancer Center explains the ESMO 2020 Abstract – Personalized molecularly matched therapies for…

Roy S Herbst, MD, Ph.D. @DrRoyHerbstYale @YaleCancer #ESMO20 #NSCLC #ADAURA Yale Cancer Center Study Reinforces Benefit Using Targeted Therapy for Early Stage NSCLC

Non-Small Cell Lung Cancer 2 Mins Read

Roy S Herbst, MD, Ph.D. of Yale Cancer Center explains the ESMO abstract – Yale Cancer Center Study Reinforces Benefit…

Ana Maria Arance Fernandez, MD @hospitalclinic #ESMO20 #melanoma #MEL LBA44 – Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL)

Melanoma Skin Cancer Treatment 3 Mins Read

Ana Maria Arance Fernandez, MD of Hospital Clínic de Barcelona, Barcelona, Spain speaks on her ESMO abstract – LBA44 -…

Alexander Eggermont, MD @GustaveRoussy #ESMO20 #melanoma Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results

Melanoma Skin Cancer Treatment 2 Mins Read

Alexander Eggermont, MD of Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay explains the ESMO 2020 abstract LBA46 -…

Zarnie Lwin, MD @zarnielwin @RBWHFoundation LBA41 – LEAP-005: Phase II study of len plus pembro in pts with previously treated AST

Liver 2 Mins Read

Zarnie Lwin, MD Royal Brisbane, and Women’s Hospital, University of Queensland discusses the ESMO abstract LBA41 – LEAP-005: Phase II…

John Bridgewater, MD, Ph.D. @uclcancer #livercancer Phase 2 Study FOENIX-CCA2 and Efficacy and Safety of Futibatinib

Liver 6 Mins Read

John Bridgewater, MD, Ph.D., Medical Oncologist discusses ESMO abstracts Efficacy and Safety of Futibatinib in Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2…

Dr. Neal Shore MD, FACS @AtlanticUrology #ESMO20 #prostatecancer Tolerability and treatment response in the phase 3 ARAMIS trial – Nonmetastatic, Castration-Resistant Prostate Cancer and …

Prostate Cancer Treatment 5 Mins Read

Dr. Neal Shore MD, FACS, CPI, of the Atlantic Urology Clinics and Director at the Carolina Urologic Research Center, discusses…

Susanna Curtis, MD @YaleCancer @YaleMed Medical Marijuana Associated with Fewer Hospitalizations for Individuals Living with SCD

Sickle Cell 3 Mins Read

Susanna Curtis, MD of Yale School of Medicine and Yale Cancer Center speaks about the Study: Medical Marijuana Associated with…

Erika P. Hamilton, MD @ErikaHamilton9 @SarahCannonDocs #ESMO20 #breastcancer LIO-1: A Phase 2 study of lucitanib + nivolumab and Initial clinical experience of lucitanib + nivolumab

Breast Cancer 1 Min Read

Erika P. Hamilton, MD Director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology speaks…

Neal Shore, MD @AtlanticUrology @Myovant #prostatecancer ESCALATE Trial Potential Enhancement of Prostate Cancer Treatment Options: First Patient Randomized in Phase III Trial

Prostate Cancer Treatment 2 Mins Read

Neal Shore, MD at the Carolina Urologic Research Center discusses the ESCALATE Trial Potential Enhancement of Prostate Cancer Treatment Options:…

Lillian Siu, MD @pmcancercentre @lillian_siu #ESMO20 #advancedsolidtumors Initial Results of a Phase 1 Study of MK-4830, a First-in-Class Anti-Immunoglobulin-Like Transcript 4

General 3 Mins Read

Lillian Siu, MD of the Princess Margaret Cancer Centre discusses ESMO 2020 abstract #524O, Proffered Paper: Initial Results of a…

Eric Jonasch, MD @MDANdersonNews #ASCO20 #renalcellcarcinoma #vonhippellindau #VHL Phase II study of the oral HIF-2α inhibitor MK-6482

General 3 Mins Read

Eric Jonasch, MD The University of Texas MD Anderson Cancer Center ASCO 2020 Phase II study of the oral HIF-2α…

Robert Coleman, MD, FACOG, FACS @USOResearch #ASCO20 #SSC #PBC #ovariancancer A phase III randomized controlled trial of secondary surgical cytoreduction

Ovarian 3 Mins Read

Robert Coleman, MD, FACOG, FACS, Chief Scientific Officer US Oncology Research discusses ASCO 2020 A phase III randomized controlled trial…

Erik A. Williams, MD @FoundationATCG #softtissuesarcoma CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1

Sarcoma 2 Mins Read

Erik A. Williams, MD of the Foundation Medicine, Inc. discusses CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor…

Paolo Ghia, MD, Ph.D. @MyUniSR #RRCLL #CLL ASCEND: Phase III, Randomized Trial of Acalabrutinib

Chronic Lymphocytic Leukemia 2 Mins Read

Paolo Ghia, MD, Ph.D. of Università Vita-Salute San Raffaele speaks about ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib…

Xiang Cheng Ph.D. and Feng Geng Ph.D. @OSUCCC_James #braincancer Blocking Fat Storage Might Offer New Way to Treat Most Lethal Form of Brain Cancer

Brain 3 Mins Read

Xiang Cheng Ph.D. and Feng Geng Ph.D. from Ohio State University Comprehensive Cancer Center discusses Blocking Fat Storage Might Offer…

S. Michelle Shiller, DO, AP/CP, MGP @PathGroupLabs @LUNGevity Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing

General 3 Mins Read

S. Michelle Shiller, DO, AP/CP, MGP at PathGroup discusses how the Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use…

Ari Melnick, MD @LabMelnick @WeillCornell @ASH_hematology American Society of Hematology Ernest Beutler Lecture and Prize

Hematologic Malignancies 2 Mins Read

Ari Melnick, MDof Weill Cornell Medicine discusses winning the  American Society of Hematology Ernest Beutler Lecture and Prize. ASH will award…

Edward J. Benz, Jr., MD @DanaFarber @DanaFarberNews @ASH_hematology @DanaFarberNews American Society of Hematology Leadership in Promoting Diversity and the road ahead

Hematologic Malignancies 3 Mins Read

Edward J. Benz, Jr., MD at Dana Farber discusses his award from American Society of Hematology Leadership in Promoting Diversity…

Ammar Chaudhry, MD @cityofhope @AACR #AACR20 #glioblastoma Randiomic prediction of survival in recurrent high-grade glioma patients

Brain 1 Min Read

Ammar Chaudhry, MD at City of Hope discusses an abstract from AACR 2020 entitled Randiomic prediction of survival in recurrent…

Shailja Shah, MD, MPH @VUMC_Cancer Study gauges specific site gastric cancer risks among ethnic groups

Gastrointestinal Cancer Treatment 3 Mins Read

Shailja Shah, MD, MPH. at Vanderbilt Ingram Cancer Center discusses a Study which gauges specific site gastric cancer risks among…

Nick Smith-Stanley, MBA @livestrong @DellMedSchool #women #oncology Addressing the Disparity of Women in Oncology and Live

General 1 Min Read

Nick Smith-Stanley, MBA, Associate Director of Administration & Strategic Planning of the LIVESTRONG Cancer Institutes, Dell Medical School speaks about…

Michael Wang, MD @michaelwangmd @MDAndersonNews @KitePharma FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed or Refractory MCL

Non-Hodgkin Lymphoma 5 Mins Read

Michael Wang, MD at MD Anderson discusses Kite Pharma’s FDA Approves First Cell-Based Gene Therapy For Adult Patients with Relapsed…

Greg Hiebert Leadership Forward @GregHiebert #leadership Leadership Resilience and Post Traumatic Growth and Live

General 1 Min Read

Greg Hiebert, Leadership Educator, Coach, and Consultant of Leadership Forward discusses Leadership Resilience and Post Traumatic Growth & Live. Great…

David R. Gandara, MD @MDAndersonNews @GuardantHealth Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw

General 2 Mins Read

David R. Gandara, MD at MDAnderson discusses Guardant Health’s FDA approval of the Guardant360 CDx which delivers critical genomic information…

Minesh P Mehta MD, FASTRO @BaptistHealthSF High- vs Low-Dose Radiation for Adult Low-Grade Glioma

Brain 1 Min Read

Minesh P Mehta MD, FASTRO @BaptistHealthSF High- vs Low-Dose Radiation for Adult Low-Grade Glioma

Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from new competitive landscape, says GlobalData

Hodgkin Lymphoma 2 Mins Read

Miguel Ferreira, MSc of GlobalData discusses how the Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from…

Stephen B. Edge MD, FACS, FASCO @RoswellPark #ASCO20 Going off pathway: Problem or good care?

Ovarian 2 Mins Read

Stephen B. Edge MD, FACS, FASCO of Roswell Park Comprehensive Cancer Center speaks about the ASCO 2020 Going off pathway:…

Kazuhiko Matsuoka, PhD @MedUni_Wien Osteosarcoma (OS) is the most common form of aggressive bone cancer. A MedUni Vienna study, led by geneticist Erwin Wagner, has uncovered new insights …

Bone Metastases 2 Mins Read

Kazuhiko Matsuoka, PhD Medical University of Vienna Osteosarcoma (OS) is the most common form of aggressive bone cancer. A MedUni…

Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-M…

Myeloproliferative Disease 2 Mins Read

Mikkael Sekeres, MD @CleClinicMD @TakedaPharma FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic…

Melissa Ann Geller, MD @UMNews #ASCO20 #ovariancancer APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer

Ovarian 3 Mins Read

Melissa Ann Geller, MD of the University of Minnesota speaks about the ASCO 2020 abstract APOLLO: A phase I study…

Marwan Fakih, MD @cityofhope #AACR20 Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study

Liver 2 Mins Read

Marwan Fakih, MD at City of Hope discusses an abstract from AACR20 entitled Efficacy and Safety of Pembrolizumab in Previously…

Anca Chelariu- Raicu, MD @MDAndersonNews #ASCO20 #ovariancancer Phase I/II study of weekly topotecan and gefitinib in patients with platinum-resistant ovarian, peritoneal, or fallopian tu…

Ovarian 3 Mins Read

Anca Chelariu- Raicu, MD of MD Anderson Cancer Center speaks about the ASCO 2020 abstract Phase I/II study of weekly…

Jennifer Baker Flechtner, Ph.D. @GenoceaBio #AACR #immunotherapy Reveal New Understanding of ATLASTM-Identified InhibigenTM Biology

Immunotherapy 2 Mins Read

Jennifer Baker Flechtner, Ph.D. – Genocea Biosciences Inc’s Chief Scientific Officer discusses Genocea to Present Data that Reveal New Understanding…

J. Mel Sorensen MD Galera #ASCO20 #galera #headandneckcancer ROMAN:(GC4419)–phase III trial in patients receiving chemoradiotherapy for locally advanced nonmetastatic head and neck cancer

Head and Neck 3 Mins Read

J. Mel Sorensen, MD President, and Chief Executive Officer Galera Thereptutics, Inc gives an overview from ASCO 2020 abstract entitled…

Petros Grivas, MD, PhD @SeattleCCA #UrothelialCancer FDA Approves Avelumab (BAVENCIO) as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carci…

Urology 2 Mins Read

Petros Grivas, MD, PhD Seattle Cancer Care Alliance discusses FDA Approves Avelumab (BAVENCIO) as First-Line Maintenance Treatment for Patients with…

Jonathan Cheng, MD @Merck #colorectalcancer KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients Approval Received Less Than One M…

Colorectal 1 Min Read

Jonathan Cheng, MD Merck – Vice President Clinical Research discusses KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the…

Aurélien Marabelle, MD @GustaveRoussy FDA Approves Second Biomarker-Based Indication for Pembrolizumab (KEYTRUDA)

General 3 Mins Read

Aurélien Marabelle, MD at Gustave Roussy discusses the FDA Approval of Second Biomarker-Based Indication for Pembrolizumab (KEYTRUDA) The FDA issued…

Chandra Belani, MD @IASLC #lungcancer IASLC: New Lung Cancer Screening Guidelines Will Save Lives

Non-Small Cell Lung Cancer 3 Mins Read

Chandra Belani, MD Chief Science Officer – IASLC discusses IASLC: New Lung Cancer Screening Guidelines Will Save Lives Scientists have…

Hui Li, PhD @UVACancerCenter UVA IDs Gene Responsible for Deadly Glioblastoma

Brain 3 Mins Read

Hui Li, PhD at Univeristy of Virginia UVA IDs Gene Responsible for Deadly Glioblastoma Scientists have found an oncogene (a…

Wendy Stock, MD @UChicagoMed @ASH_hematology 2020 Mentor Award Recipient

General 2 Mins Read

Wendy Stock, MD of University of Chicago receives 2020 Mentor Award Recipient The Anjuli Seth Nayak Professor of Leukemia at…

Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead

Immunotherapy 1 Min Read

Sigrun Hallmeyer, MD at ACCC discusses Immuno-Oncology and What Lies Ahead

Michael Wang, MD @michaelwangmd @MDAndersonNews Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Lymphoma 8 Mins Read

Michael Wang, MD from MD Anderson discusses a paper from Nature entitled Durable response with single-agent acalabrutinib in patients with…

Steve Shak @ExactSciences Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfavorable Intermediate-Risk Prostate Ca…

Prostate Cancer Treatment 1 Min Read

Steve Shak Exact Sciences Chief Medical Officer discusses Oncotype DX Genomic Prostate Score® Result Shows for the First Time the…

Timothy A. Yap, MD @MDAndersonNews #ASCO20 Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid T…

General 2 Mins Read

Timothy A. Yap, MD from MD Anderson discusses an abstract from Journal of Clinical Oncology entitled Phase I Trial of…

Christopher Jakubowski, MD @HopkinsMedicine #ASCO20 Response to Crizotinib in ROS1 Fusion–Positive Intrahepatic Cholangiocarcinoma

Liver 1 Min Read

Christopher Jakubowski, MD The Johns Hopkins discusses an abstract from The Journal of Clinical Oncology entitled Response to Crizotinib in…

Murray Brunt, MBBS, FRCR, FRCP @ICR_London #ASCO20 Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

Breast Cancer 2 Mins Read

Murray Brunt, MBBS, FRCR, FRCP The Institute of Cancer discusses an article in The Journal of Clinical Oncology entitled Ten-Year…

Daniel Persky, MD @UAZCance #ASCO20 Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical …

Lymphoma 2 Mins Read

Daniel Persky, MD @UAZCance #ASCO20 Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup…

Dan Paul Zandberg, MD @UPMCnews #ASCO20 The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M)

Head and Neck 3 Mins Read

Dan Paul Zandberg, MD at UPMC discusses an ASCO 2020 abstract entitled The impact of tumor hypoxia on the clinical…

Ari Rosenberg, MD @UChicagoMed #ASCO20 Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial

Gastrointestinal Cancer Treatment 2 Mins Read

Ari Rosenberg, MD at The University of Chicago discusses an abstract from ASCO 2020 entitled Dose and volume de-escalation for…

Professor Galina Velikova, MD @UniversityLeeds @NIH #eRAPID Phase III randomized controlled trial of eRAPID An eHealth intervention during chemotherapy

General 3 Mins Read

Professor Galina Velikova, MD of the Leeds Institute of Medical Research discusses the ASCO abstract Phase III randomized controlled trial…

Jingxuan Zhao, MPH @AmercianCancer #ASCO20 Health insurance status and cancer stage at diagnosis and survival in the United States

General 2 Mins Read

Jingxuan Zhao, MPH @AmercianCancer #ASCO20 Health insurance status and cancer stage at diagnosis and survival in the United States Bottom…

Paz J. Vellanki, MD @FDAOncology @PazVallanki Evaluation of the correlation between antibiotic use and survival in patients with recurrent or metastatic head and neck squamous cell carcin…

Head and Neck 2 Mins Read

Paz J. Vellanki, MD from U.S. Department of Health and Human Services discusses an ASCO 2020 abstract entitled Evaluation of…

Nikhil C. Munshi, MD @DanaFarber @bmsnews @bluebirdbio #RRMM #ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory…

Multiple Myeloma 2 Mins Read

Nikhil C. Munshi, MD of Dana-Farber Cancer Institute discusses ASCO20 Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in…

Lillian Siu, MD @pmcancercentre #ASCO20 Phase III LEAP-010 study: first-line pembrolizumab with or without lenvatinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (…

Head and Neck 2 Mins Read

Lillian Siu, MD Princess Margaret Cancer Centre discusses an ASCO 2020 abstract entitled Phase III LEAP-010 study: first-line pembrolizumab with…

Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential

Liver 3 Mins Read

Bruno Sangro, MD, Ph.D. at Clinica Universidad de Navarro discusses The unmet need in HCC patients, the ADP-A2AFP complete response…

Manisha H Shah, MD @OSUCCC_James Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

Acute Myelogenous Leukemia 3 Mins Read

Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center explains the study: Dabrafenib, Trametinib, and IMRT…

Andrew Wei, MBBS, Ph.D. @MonashUni @US_FDA U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New Oral Therapy, as Continued Treatment for Adults in First Remiss…

Acute Myelogenous Leukemia 8 Mins Read

Andrew Wei, MBBS, Ph.D. Alfred Hospital and Monash University U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets), a New…

Catherine Haring, MD & Paul Swiecicki, MD @UMichMedAdmiss #ASCO20 HPV ctDNA analysis in unresectable recurrent/metastatic oropharyngeal cancer

Head and Neck 2 Mins Read

Catherine Haring, MD & Paul Swiecicki, MD from University of Michigan Medical School discuss an ASCO 2020 abstract entitled HPV…

Ralph Zinner, MD @UK_HealthCare #ASCO20 Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer

Head and Neck 3 Mins Read

Ralph Zinner, MD University of Kentucky discusses an ASCO 2020 abstract entitled Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and…

Manisha H Shah MD @OSUCCC_James #thyroidcancer #medullary Efficacy of Selpercatinib in RET-Altered Thyroid Cancers

General 2 Mins Read

Manisha H Shah, MD of The James Ohio State University Comprehensive Cancer Center discusses the Efficacy of Selpercatinib in RET-Altered…

Jan Ole Kemnade, MD, Ph.D. @bcmhouston #ASCO20 Computational discovery of non-mutational tumor-restricted antigens reveals evidence of immunoediting in head and neck squamous cell carcino…

Ovarian 3 Mins Read

Jan Ole Kemnade, MD, Ph.D. from Baylor College of Medicine discusses and ASCO 2020 abstract entitled Computational discovery of non-mutational…

Rebecca Christian Arend, MD @UABSOM #ASCO20 Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian canc…

Ovarian 2 Mins Read

Rebecca Christian Arend, MD at University of Alabama discusses an abstract from ASCO 2020 Clinical trial in progress: Pivotal study…

Michelle Echevarria, MD @MoffittNews #ASCO20 Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and…

Head and Neck 3 Mins Read

Michelle Echevarria, MD from Moffitt Cancer Center discusses an ASCO 2020 Phase I dose escalation of stereotactic body radiation therapy…

Kedar Kirtane, MD @MoffittNews #ASCO20 Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Re…

Head and Neck 3 Mins Read

Kedar Kirtane, MD from Moffitt Cancer Center discusses an ASCO 2020 abstract entitled Concurrent cetuximab (CTX) and nivolumab (NIVO) in…

Kathleen N. Moore, MD @OUMedicine #ASCO20 MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label, phase III study of mirvetuximab soravtansine versus investigator’s choice of chemothe…

Ovarian 2 Mins Read

Kathleen N. Moore, MD from OU Medicine discusses an ASCO 2020 abstract entitled MIRASOL (GOG 3045/ENGOT OV-55): A randomized, open-label,…

Denise Manon Langabeer MBA Ph.D. @MDAndersonNews #ASCO20 #ovariancancer Are symptoms distinguishable in ovarian cancer

Ovarian 3 Mins Read

Denise Manon Langabeer, MBA, Ph.D. of MD Anderson gives an overview from ASCO 2020 the abstract entitled Are symptoms distinguishable…

Ben George, MD @Froedtert #ASCO20 A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to pati…

General 2 Mins Read

Ben George, MD from Froedtert & Medical College discusses an ASCO 2020 abstract entitied A phase I, first-in-human, open-label, dose‑escalation,…

Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. #ASCO20 @MDAndersonNews – DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in comb…

Cervical 3 Mins Read

Shannon N. Westin, M.D., M.P.H., F.A.C.O.G. from MD Anderson discusses an ASCO 2020 abstract entitled – DUO-E/GOG-3041/ENGOT-EN10: a randomized phase…

Smita Bhatia, MD of UAB #ASCO20 Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report

Hematologic Malignancies 2 Mins Read

Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of Smita Bhatia,…

Jan Schellens MD CMO @byondis #SYD1875 #cancer Byondis Initiates Phase I Study of Antibody-Drug Conjugate SYD1875

General 5 Mins Read

Jan Schellens, MD, CMO Byondis discusses the Phase I Study of Antibody-Drug Conjugate SYD1875. 11 August 2020, Nijmegen, The Netherlands,…

Mansoor Raza Mirza, MD @RegionH #ASCO20 Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent plat…

Ovarian 2 Mins Read

Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination…

Andreas Burchert, MD University Hospital Giessen and Marburg Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Interna…

Acute Myelogenous Leukemia 2 Mins Read

Andreas Burchert, MD University Hospital Giessen and Marburg Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia…

Sepideh Azarianpour-Esfahani, Ph.D. of #ASCO20 Case Western Reserve University Computerized features of spatial arrangement of tumor-infiltrating lymphocytes from H&E images predicts sur…

Ovarian 2 Mins Read

Sepideh Azarianpour-Esfahani, Ph.D. of Case Western Reserve University discusses an abstract from ASCO 2020 Computerized features of spatial arrangement of…

Nicolo Manaresi Ph.D. CSO @SiliconBio #AACR #cancermechanisms #cancer Deepen Understanding Of Cancer Mechanisms

General 3 Mins Read

Nicolo Manaresi, Ph.D. Chief Scientific Officer of M Silicon Biosystems gives an overview of Two Studies Presented at AACR 20…

Allison Huegel COO of AxoProtego and Ahmet Hoke, MD, Ph.D. @HopkinsMedicine #chemotherapyinducedperipheralneuropathy #neuropathy Novel Investigational Agent for Chemotherapy-Induced Perip…

General 3 Mins Read

Allison Huegel, COO AxoProtego and Ahmet Hoke, MD, Ph.D. Johns Hopkins Medicine gives an overview of AxoProtego Therapeutics Announces Novel…

John R. Jack Steel M.D. F.A.C.R.O. @tbropa #Anxiety #cancertreatment Managing Anxiety During Cancer Treatment

Other 3 Mins Read

John R. “Jack” Steel, M.D. F.A.C.R.O. of Tampa Bay Radiation Oncology discusses Managing Anxiety During Cancer Treatment. Some of the…

David Spetzler M.S. Ph.D. MBA @CarisLS #solidtumors #genefusions Advance Enrollment in Phase 2 Trial of Patients with Solid Tumors Harboring NRG1 Gene Fusions

General 3 Mins Read

David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris Life Sciences discusses their Partners with Elevation Oncology…

Rana R. McKay, MD @DrRanaMcKay @UCSDHealth #ASCO20 Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (O…

Kidney 3 Mins Read

Rana R. McKay, MD UC SD Health discusses ASCO 2020 abstract entitled Optimized management of nivolumab (Nivo) and ipilimumab (Ipi)…

Benoit You, MD, Ph.D. @CHUdeLyon #ASCO20 ROPHIMMUN phase II trial, cohort A

Gastrointestinal Cancer Treatment 3 Mins Read

Benoit You, MD, Ph.D. from Centre Hospitalier Lyon-Sud discusses an ASCO 2020 abstract entitled ROPHIMMUN phase II trial, cohort A…

Babar Bashir, MD @TJUHospital #ASCO20 BT5528-100 phase I/II study of the safety, pharmacokinetics, and preliminary clinical activity of BT5528 in patients with advanced malignancies asso…

General 2 Mins Read

Babar Bashir, MD from Jefferson Health discussed an ASCO 2020 abstract entitled BT5528-100 phase I/II study of the safety, pharmacokinetics,…

Johanna C. Bendell, MD @SarahCannonDocs #ASCO20 A phase I/II, two-part, multicenter, first-in-human study of DS-7300a in patients with advanced solid malignant tumors

Gastrointestinal Cancer Treatment 2 Mins Read

Johanna C. Bendell, MD from Sarah Cannon discusses and ASCO 2020 abstract entitled A phase I/II, two-part, multicenter, first-in-human study…

Ramaprasad Srinivasan, M.D., Ph.D. – @NCIResearchCtr #ASCO20 Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell …

Kidney 3 Mins Read

Ramaprasad Srinivasan, M.D., Ph.D. – NIH National Cancer Institute Results from a phase II study of bevacizumab and erlotinib in…

David A. Braun, MD, PhD @DanaFarber #ASCO20 Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade

Kidney 3 Mins Read

David A. Braun, MD, PhD from Dana Farber discusses an ASCO 2020 abstract entitled Immunogenomic characterization of advanced clear cell…

Paola Nix, Ph.D. @myriadgenetics #ASCO20 Functional RNA Studies Are a Useful Tool in Variant Classification but Must Be Used With Caution: A Case Study of One BRCA2 Variant

Breast Cancer 8 Mins Read

Paola Nix, Ph.D. at Myriad Genetics discusses an ASCO 2020 abstract entitled Functional RNA Studies Are a Useful Tool in…

Thanh Hue Dellinger, MD @cityofhope #ASCO20 Whole transcriptome changes correlate to exceptional ovarian cancer responders: A sub-analysis of a HIPEC Phase I trial

Ovarian 2 Mins Read

Thanh Hue Dellinger, MD from the City of Hope discusses an ASCO 2020 abstract entitled Whole transcriptome changes correlate to…

Patrick Glen Pilie, MD @MDAndersonNews #ASCO20 Identifying Functional Loss of ATM Gene In Patients With Advanced Cancer

General 3 Mins Read

Patrick Glen Pilie, MD MD Anderson discusses an ASCO 2020 abstract entitled Identifying Functional Loss of ATM Gene In Patients…

Matthew Galsky, MD @MattGalsky @TischCancer #ASCO20 Phase III IMvigor130 Study Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + pla…

Prostate Cancer Treatment 2 Mins Read

Matthew Galsky, MD from Mount Sinai Tisch Cancer discusses an ASCO 2020 abstract entitled Phase III IMvigor 130 Study Tumor,…

Eleni Efstathiou, MD, Ph.D. @EfstathiouEleni @MDAndersonNews #ASCO20 Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate…

Prostate Cancer Treatment 3 Mins Read

Eleni Efstathiou, MD, Ph.D. of MD Anderson discusses an ASCO 2020 abstract entitled Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with…

Ajay Goel Ph.D. @cityofhope #AACR #gastrointestinalcancer A cell free DNA methylation fingerprint for the early detection of gastrointestinal cancer

Gastrointestinal Cancer Treatment 3 Mins Read

Ajay Goel, Ph.D. of the City of Hope speaks about the AACR 2020 Abstract 1084: EpiPanGI-Dx: A cell-free DNA methylation…

David Spigel, MD @dave6408 @SarahCannonDocs #ACCC Results Show Multidisciplinary Team Approach Needed for Best Care, Outcomes

Non-Small Cell Lung Cancer 3 Mins Read

David Spigel, MD at Sarah Cannon discusses an ACCC 2020 presentation entitled Results Show Multidisciplinary Team Approach Needed for Best…

Nancy Beatriz Gordon, MD @MDAndersonNews #ASCO20 A Phase I Trial Of Aerosol Gemcitabine For The Treatment Of Patients With Solid Tumors And Lung Metastases

Non-Small Cell Lung Cancer 3 Mins Read

Nancy Beatriz Gordon, MD from MD Anderson discusses an abstract from ASCO 2020 entitled A Phase I Trial Of Aerosol…

Istvan Petak, MD #ASCO20 Oncompass Medicine SHIVA01 Trial Update

General 2 Mins Read

Istvan Petak, MD #ASCO20 Oncompass Medicine SHIVA01 Trial Update Context: Precision oncology demands that individual molecular pathomechanisms be identified in…

Scott Kopetz, MD @skopetz @MDAndersonNews FDA Approves Braftovi® (Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant Metastatic Colorectal Cancer

Colorectal 2 Mins Read

Scott Kopetz, MD at MD Anderson discusses the FDA Approval Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant…

Sonny Hsiao Ph.D. @AcepodiaInc #AACR #ovariancancer #ACE1702 Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II – Final Thoughts

Ovarian 3 Mins Read

Sonny Hsiao, Ph.D. of Acopedia shares his final thoughts on Acepodia Presents Preclinical Data on its Lead NK Cell Therapy…

Sonny Hsiao Ph.D. @AcepodiaInc #AACR #ovariancancer #ACE1702 Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020 AACR Virtual Meeting II

Ovarian 3 Mins Read

Sonny Hsiao, Ph.D. of Acopedia discusses Acepodia Presents Preclinical Data on its Lead NK Cell Therapy Candidate ACE1702 at 2020…

Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine – Final Thoughts

Uterine 6 Mins Read

Alessandro Santin, MD of Byondis shares his final thoughts on the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate…

Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine – What Are The Next Steps

Uterine 6 Mins Read

Alessandro Santin, MD of Byondis talks about what are the next steps for the study: Byondis Initiates Phase II Study…

Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine – Will This Affect Clinicians Today

Uterine 6 Mins Read

Alessandro Santin, MD of Byondis speaks about will this affect clinicians today on the study: Byondis Initiates Phase II Study…

Jeff Ross, MD @FoundationATCG #ASCO20 Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study

Breast Cancer 3 Mins Read

Jeff Ross, MD at Foundation Medicine discusses an ASCO 2020 abstract entitled Clinically aggressive malignancies associated with STK11 germline mutations…

Theresa Deisher PhD @avmbiotech The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

Lymphoma 6 Mins Read

Theresa Deisher PhD at AVM Biotechnology discusses The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma Description in detail:…

Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS

General 2 Mins Read

Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS The optimisation of the…

Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine – Common Questions

Uterine 6 Mins Read

Alessandro Santin, MD of Byondis answers common questions on the study: Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab…

Alessandro Santin MD @byondis #uterinecancer Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine

Uterine 6 Mins Read

Alessandro Santin, MD of Byondis talks about the study: Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced…

Ignacio Garrido-Laguna, MD @huntsmancancer #ASCO20 TP‑3654 administered daily for 28 days to patients with advanced solid tumors

General 2 Mins Read

Ignacio Garrido-Laguna, MD at Huntsman Cancer Institute discusses the ASCO 2020 abstract entitled A phase I, first-in-human, open-label, dose‑escalation, safety,…

Oliver Peacock MD @MDAndersonNews #colorectalcancer #ASCO20 Improving the AJCC/TNM staging classification for colorectal cancer – Final Thoughts

Colorectal 2 Mins Read

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center gives his final thoughts about his ASCO 2020 Abstract…

Oliver Peacock MD @MDAndersonNews #colorectalcancer #ASCO20 Improving the AJCC/TNM staging classification for colorectal cancer – Common Questions

Colorectal 2 Mins Read

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center answers common questions he has received for his ASCO…

Oliver Peacock MD @MDAndersonNews #colorectalcancer #ASCO20 Improving the AJCC/TNM staging classification for colorectal cancer

Colorectal 2 Mins Read

Oliver Peacock, MD The University of Texas MD Anderson Cancer Center discusses his ASCO 2020 Abstract on Improving the AJCC/TNM…

Philip Mack Ph.D. @MountSinai #nonsmallcelllungcancer #NSCLC Residual ctDNA after two months of therapy to predict progression-free and overall survival in patients – Common Questions

Non-Small Cell Lung Cancer 2 Mins Read

Philip Mack, Ph.D. of Mount Sinai answers the common questions he has received for his ASCO 2020 abstract on Residual…

Philip Mack Ph.D. @MountSinai #nonsmallcelllungcancer #NSCLC Residual ctDNA after two months of therapy to predict progression-free and overall survival in patients

Non-Small Cell Lung Cancer 2 Mins Read

Philip Mack, Ph.D. of Mount Sinai discusses his ASCO 2020 abstract on Residual circulating tumor DNA (ctDNA) after two months…

Senthil Damodaran MD @MDAndersonNews #ASCO20 #solidtumors #lymphomas #multiplemyeloma Phase II study of copanlisib in patients with tumors with PIK3CA mutations – Final Thoughts

Lymphoma 3 Mins Read

Senthil Damodaran, MD of MD Anderson shares his final thoughts on the Phase II study of copanlisib in patients with…

Senthil Damodaran MD @MDAndersonNews #ASCO20 #solidtumors #lymphomas #multiplemyeloma Phase II study of copanlisib in patients with tumors with PIK3CA mutations – Common Questions

Lymphoma 3 Mins Read

Senthil Damodaran, MD of MD Anderson talks about the common questions he receives about the Phase II study of copanlisib…

Wilson H. Miller, MD @CIUSSS_COMTL #ASCO20 A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer.

General 3 Mins Read

Wilson H. Miller, MD Jewish General Hospital discusses an ASCO 2020 abstract entitled A phase Ib study of oral Chk1…

Senthil Damodaran MD @MDAndersonNews #ASCO20 #solidtumors #lymphomas #multiplemyeloma Phase II study of copanlisib in patients with tumors with PIK3CA mutations

Lymphoma 3 Mins Read

Senthil Damodaran, MD of MD Anderson explains the Phase II study of copanlisib in patients with tumors with PIK3CA mutations…

Jason P Sheehan MD @uvahealthnews #glioblastoma Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Final Thoughts

Brain 4 Mins Read

Jason P Sheehan, MD of the University of Virginia speaks about his final thoughts on the Focused Ultrasound Shows Potential…

Lindsey Rolfe @clovisoncology New Preclinical Data on ALKS 4230 in Combination With Lucitanib

Colorectal 4 Mins Read

Lindsey Rolfe at Clovis Oncology outlines a New Preclinical Data on ALKS 4230 in Combination With Lucitanib The research assessed…

Jason P Sheehan MD @uvahealthnews #glioblastoma Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Will This Affect Clinicians Today

Brain 4 Mins Read

Jason P Sheehan, MD of the University of Virginia explains how this will affect clinicians today, the Focused Ultrasound Shows…

Jason P Sheehan MD @uvahealthnews #glioblastoma Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Common Questions

Brain 4 Mins Read

Jason P Sheehan, MD of the University of Virginia discusses the common questions he receives about the Focused Ultrasound Shows…

Daniel Becker MD @NYULMC #ASCO20 Exploring the Cancer Genome Atlas (TCGA) for the molecular profile of young onset colorectal cancers

Colorectal 3 Mins Read

Daniel Becker MD at NYU Langone discusses an ASCO 2020 abstract entitled Exploring the Cancer Genome Atlas (TCGA) for the…

Jason P Sheehan MD @uvahealthnews #glioblastoma Focused Ultrasound Shows Potential Against Deadliest Brain Tumor

Brain 3 Mins Read

Jason P Sheehan, MD of the University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor. The…

Kristen Hege MD @bmsnews Phase 1 proof-of-concept data on novel CELMoD CC-92480 – Common Questions – #ASCO20 #relapsedrefractorymultiplemyeloma #RRMM

Multiple Myeloma 3 Mins Read

Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…

Filip Janku, MD @FilipJankuMD @MDAndersonNews #ASCO20 Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

General 3 Mins Read

Filip Janku, MD at MD Anderson discusses an ASCO 2020 abstract entitled Phase I study of IM156, a novel potent…

Kristen Hege MD @bmsnews Phase 1 proof-of-concept data on novel CELMoD CC-92480 – Kristen Hege MD – Bristol Myers Squibb #ASCO20 #relapsedrefractorymultiplemyeloma #RRMM

Multiple Myeloma 3 Mins Read

Kristen Hege, MD – Bristol Myers Squibb discusses Phase 1 proof-of-concept data (via an oral presentation) on novel CELMoD CC-92480…

Haiying Cheng, MD @albertacancer #ASCO20 RICTOR amplification as a novel therapeutic target for lung cancer brain metastases

Non-Small Cell Lung Cancer 2 Mins Read

Haiying Cheng, MD at Albert Einstein Cancer Center discusses an ASCO 2020 abstract entitled RICTOR amplification as a novel therapeutic…

Philip McCarthy, MD @PLMcCarthyMD @RoswellPark New Strategy for Controlling Graft vs. Host Disease in Blood/Marrow Transplant Recipients

Hematologic Malignancies 4 Mins Read

Philip McCarthy, MD of Roswell Park discusses New Strategy for Controlling Graft vs. Host Disease in Blood/Marrow Transplant Recipients. New…

Charles Edward Geyer, MD @MethodistHosp #ASCO20 Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual…

Breast Cancer 3 Mins Read

Charles Edward Geyer, MD Houston Methodist discusses the ASCO 2020 abstract entitled Biomarker data from KATHERINE: A phase III study…

Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.

Immunotherapy 3 Mins Read

Jacob J. Adashek, DO of Moffit Cancer Center gives an overview from ASCO 2020 the abstract entitled Targetable immune checkpoint…

Ravi Salgia, MD, PhD @cityofhope #AACR20 Association of molecular characteristics with survival in advanced NSCLC patients treated with checkpoint inhibitors

Non-Small Cell Lung Cancer 3 Mins Read

Ravi Salgia, MD, PhD from City of Hope and the AACR 2020 meeting discusses the AACR 2020 abstract entitled Association…

Cathy Eng, MD @CathyEngMD @VUMChealth Anal cancer’s first randomized trial for inoperable disease sets the treatment standard

Colorectal 3 Mins Read

Cathy Eng, MD at Vanderbilt University Medical Center discusses Anal cancer’s first randomized trial for inoperable disease sets the treatment…

Strata Partners with Elevation Oncology – CRESTONE Study for Patients with Rare NRG1 Gene Fusions – Scott Tomlins MD Ph.D. – @StrataOncology #rareNRG1 #NRG1genefusions

General 3 Mins Read

Scott Tomlins, MD, Ph.D. Co-Founder, and Chief Scientific Officer – Strata discusses the Strata Oncology Partners with Elevation Oncology to…

Astellas – Annual C3 Prize® Call for Entries – Award the Best Innovations in Cancer Care Beyond Medicine – Audrey Guth, Nanny Angel Network – Astellas Oncology @nannyangels @AstellasUS #…

General 1 Min Read

Audrey Guth, Nanny Angel Network – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award…

Eric Jonasch, MD @MDAndersonNews #ASCO2020 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease @EJonasch

Kidney 3 Mins Read

Eric Jonasch, MD @MDAndersonNews #ASCO2020 gives an overview of the Phase II study of the oral HIF-2α inhibitor MK-6482 for…

Astellas – Annual C3 Prize® Call for Entries – Award the Best Innovations in Cancer Care Beyond Medicine – Abby Westerman founder of b-present Foundation – Astellas @bpresentorg @Astella…

Other 1 Min Read

Abby Westerman, founder of b-present Foundation – Astellas discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award…

Elizabeth Plimack, MD @ERPlimackMD @FoxChaseCancer #ASCO20 Updated analysis of KEYNOTE-426

Kidney 3 Mins Read

Elizabeth Plimack, MD @FoxChaseCancer gives an updated analysis of KEYNOTE-426 at ASCO 2020 Pembrolizumab plus axitinib versus sunitinib as first-line…

Jared Gollob @JaredGollob @KymeraTx #AACR20 What’s the Advantage of IRAK4 Combined into One Molecule

Immunotherapy 4 Mins Read

Jared Gollob Chief Medical Officer @KymeraTx shares common questions he gets from colleagues such as “What’s Advantage of IRAK 4…

Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders

Immunotherapy 4 Mins Read

Jared Gollob @JaredGollob @KymeraTx gives an overview of a poster presented at AACR 2020 IRAKIMiD Degrader Program and Present Preclinical…

Astrid Margossian, MD @SEngineMedicine Predictive value of a CLIA-approved organoid based drug sensitivity test

General 2 Mins Read

Astrid Margossian, MD @SEngineMedicine discusses an ASCO 2020 poster entitled Predictive value of a CLIA-approved organoid based drug sensitivity test…

Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the Best Innovations in Cancer Care Beyond Medicine – Andy Krivoshik, MD, Ph.D – Astellas @AstellasUS #C3Prize

Other 1 Min Read

Andy Krivoshik, MD, Ph.D. – Astellas Oncology discusses Astellas Oncology Opens Annual C3 Prize® Call for Entries to Award the…

Robin Kate Kelley, MD @UCSF Most effective way to combined a CTL4 inhibitor with a PDL1 inhibitor

Liver 2 Mins Read

Robin Kate Kelley, MD of the University of California, San Francisco discusses the most effective way to combined a CTL4…

Robin Kate Kelley, MD @UCSF Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepato…

Liver 2 Mins Read

Robin Kate Kelley, MD gives an overview of a presentation from ASCO 2020 entitled Efficacy, tolerability, and biologic activity of…

Charles S. Fuchs, MD, MPH @YaleCancer Checkpoint Inhibitors are a “real player” in Gastric Cancer

Gastrointestinal Cancer Treatment 2 Mins Read

Charles S. Fuchs, MD, MPH at Yale Cancer discusses how Checkpoint Inhibitors are a “real player” in Gastric Cancers. Bottom…

Charles S. Fuchs, MD, MPH @YaleCancer Current Role for Pembrolizumab in Gastric Cancer

Gastrointestinal Cancer Treatment 2 Mins Read

Charles S. Fuchs, MD, MPH at Yale Cancer discusses the Current Role for Pembrolizumab in Gastric Cancer using the latest…

Charles S. Fuchs, MD, MPH @YaleCancer Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Upda…

Gastrointestinal Cancer Treatment 2 Mins Read

Charles S. Fuchs, MD, MPH at Yale Cancer gives an overview of a study presented at ASCO 2020 entitled Pembrolizumab…

Study Findings: DNA that Pinpoint Risks for Cancers – Benjamin Tycko, MD @HMHNewJersey

News 2 Mins Read

Benjamin Tycko, MD of Hackensack Meridian Health explains his study findings on DNA that Pinpoint Risks for Cancers. By sequencing…

Classical Cancer Epigenetic vs Epigenetic Mapping – Benjamin Tycko, MD @HMHNewJersey

News 2 Mins Read

Benjamin Tycko, MD of Hackensack Meridian Health explains Classical Cancer Epigenetic vs Epigenetic Mapping. By sequencing entire genomes for DNA…

Signposts in DNA that Pinpoint Risks for Cancers and other Diseases – Benjamin Tycko, MD @HMHNewJersey

News 2 Mins Read

Benjamin Tycko, MD gives an overview of Signposts in DNA that Pinpoint Risks for Cancers and other Diseases. By sequencing…

Improving the Lives of Americans with Sickle Cell Disease Roundtable

Sickle Cell 1 Min Read

First Lady Melania Trump chairs a White House roundtable discussing sickle cell anemia. 

The Power of RNA Profiling

Colorectal 2 Mins Read

Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the power of RNA profiling now and in the future. This data…

Detecting Inflammation of Tumor using RNA profiling

Colorectal 2 Mins Read

Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the future of RNA profiling and using it for detecting inflammation of…

How HGT is Different than RNA Platform comparison of HTG EdgeSeq and RNA-Seq

Colorectal 2 Mins Read

Marian Navratil, P.h.D. of HTG Molecular Diagnostics How HGT is Different than RNAPlatform comparison of HTG EdgeSeq and RNA-Seq for…

Platform comparison of HTG EdgeSeq and RNA-Seq for gene expression profiling of tumor tissue specimens

Colorectal 2 Mins Read

Marian Navratil, P.h.D. of HTG Molecular Diagnostics gives an overview from ASCO 2020 the Platform comparison of HTG EdgeSeq and…

Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer – In Conclusion – Melissa Lynne Johnson MD – Sarah Cannon Research Institute @SarahCannonPR #…

Lymphoma 1 Min Read

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…

Availability of Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer

Colorectal 1 Min Read

Kathryn Lang, MD – Guardant Health, is this available today. The data presented at the AACR 2020 show that the…

Restricting Cohort to Negative Test Results with Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer

Colorectal 1 Min Read

Kathryn Lang, MD of Guardant Health discusses Restricting Cohort to Negative Test Results with Liquid Biopsy Highly Accurate in Detecting…

Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer Overview

Colorectal 1 Min Read

Kathryn Lang, MD of Guardant Health provides an overview of data presented at AACR 2020 that shows that the LUNAR-2…

Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer – Melissa Lynne Johnson MD – Sarah Cannon Research Institute @SarahCannonPR #advancedcancer

Lymphoma 1 Min Read

Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…

Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Jason P Sheehan MD – In conclusion – University of Virginia @uvahealthnews #glioblastoma

Brain 1 Min Read

Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor

Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Jason P Sheehan MD – Will this affect clinicians – University of Virginia @uvahealthnews #glioblastoma

Brain 1 Min Read

Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor

Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Jason P Sheehan MD – Common Questions – University of Virginia @uvahealthnews #glioblastoma

Brain 1 Min Read

Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor

Focused Ultrasound Shows Potential Against Deadliest Brain Tumor – Jason P Sheehan MD – University of Virginia @uvahealthnews #glioblastoma

Brain 1 Min Read

Jason P Sheehan, MD – University of Virginia discusses the Focused Ultrasound Shows Potential Against Deadliest Brain Tumor https://news.virginia.edu/content/focused-ultrasound-shows-potential-against-deadliest-brain-tumor

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting ADC – Preliminary results in Pts with previously treated metastatic OC or NSCLC – Debra L. Richardson MD – Sarah Cannon @Sara…

Ovarian 1 Min Read

Debra L. Richardson, MD – Sarah Cannon discusses Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC):…

Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers – J. Silvio Gutkind PhD – In Conclusion – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers…

Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers – J. Silvio Gutkind PhD – Common Questions – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers…

Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers – J. Silvio Gutkind PhD – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Precision Medicine Identifies Key Recurring Mutation in Head and Neck Cancers…

Preclinical Data Supporting the Combination of VS-6766 and Defactinib – J. Silvio Gutkind PhD – In Conclusion – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of…

Preclinical Data Supporting the Combination of VS-6766 and Defactinib – J. Silvio Gutkind PhD – Common Questions – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of…

Preclinical Data Supporting the Combination of VS-6766 and Defactinib – J. Silvio Gutkind PhD – UC San Diego @UCSDHealth #headandneckcancer

Head and Neck 1 Min Read

J. Silvio Gutkind, PhD – UC San Diego discusses Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of…

FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML – In Conclusion – Gu…

Chronic Myelogenous Leukemia 1 Min Read

Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…

FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML – Common Questions -…

Chronic Myelogenous Leukemia 1 Min Read

Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…

FDA and Health Canada approval of INQOVI® (decitabine and cedazuridine) tablets, oral hypomethylating agent (HMA) therapy for intermediate and high-risk MDS and CMML – Guillermo Garcia-M…

Chronic Myelogenous Leukemia 1 Min Read

Guillermo Garcia-Manero, MD – MD Anderson Cancer Center discusses Astex Pharmaceuticals, Taiho Oncology, and Otsuka Pharmaceutical announce FDA and Health…

Genomically informed longitudinal monitoring of circulating tumor DNA – Common Questions – Mohamed Alaa Gouda MD – MD Anderson @MDAndersonNews #advancedsolidcancers

General 1 Min Read

Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…

Genomically informed longitudinal monitoring of circulating tumor DNA – Mohamed Alaa Gouda MD – MD Anderson @MDAndersonNews #advancedsolidcancers

General 1 Min Read

Mohamed Alaa Gouda, MD MD Anderson discusses Genomically informed longitudinal monitoring of circulating tumor DNA (ctDNA) to predict outcomes of…

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine – Will it affect clinicians – Quincy S. Chu MD – University of Alberta @UAlberta #advancedcancer #metasta…

Ovarian 1 Min Read

Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination…

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine – Quincy S. Chu MD – University of Alberta @UAlberta #advancedcancer #metastaticcancer #ovariancancer

Ovarian 1 Min Read

Quincy S. Chu, MD – University of Alberta discusses A phase Ib study of oral Chk1 inhibitor LY2880070 in combination…

Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells – In Closing – John Williams Ph.D. – City of Hope @cityofhope #cartcells #CAR-T

Immunotherapy 1 Min Read

John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…

Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells – Will this affect clinicians – John Williams Ph.D. – City of Hope @cityofhope #cartcells #…

Immunotherapy 1 Min Read

John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…

Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells – Common Questions – John Williams Ph.D. – City of Hope @cityofhope #cartcells #CAR-T

Immunotherapy 1 Min Read

John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…

Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor cells – John Williams Ph.D. – City of Hope @cityofhope #cartcells #CAR-T

Immunotherapy 1 Min Read

John Williams, Ph.D. – City of Hope discusses Antibody based redirection of meditope CAR-T cells selectively kill antigen bearing tumor…

Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows – Daniel Spakowicz Ph.D. – In Conclusion – The Ohio State University Comprehensive Cancer Center @dspakow…

Immunotherapy 1 Min Read

Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…

Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows – Daniel Spakowicz Ph.D. – Next Steps for Research – The Ohio State University Comprehensive Cancer Cente…

Immunotherapy 1 Min Read

Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…

Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows – Daniel Spakowicz Ph.D. – Common Questions – The Ohio State University Comprehensive Cancer Center @dspa…

Immunotherapy 1 Min Read

Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…

Microbiome Might Reveal Whether Immune Therapy Can Benefit a Patient, Study Shows – Daniel Spakowicz Ph.D. – The Ohio State University Comprehensive Cancer Center @dspakowicz @OSUCCC_Jame…

Immunotherapy 1 Min Read

Daniel Spakowicz, PhD – The James – Ohio State University Comprehensive Cancer Center discusses Microbiome Might Reveal Whether Immune Therapy…

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor agonist GSK3359609 with platinum+5-FU chemotherapy with or without pembrolizumab for the treat…

Head and Neck 1 Min Read

Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist…

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor agonist GSK3359609 with platinum+5-FU chemotherapy with or without pembrolizumab for the treat…

Head and Neck 1 Min Read

Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist…

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor agonist GSK3359609 with platinum+5-FU chemotherapy with or without pembrolizumab for the treat…

Head and Neck 1 Min Read

Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist…

Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck – In Conclusion – Michael G. McCusker Jr. …

Head and Neck 1 Min Read

Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin…

Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck – Common Questions – Michael G. McCusker J…

Head and Neck 1 Min Read

Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin…

Cisplatin every three weeks versus weekly cisplatin or carboplatin with definitive radiotherapy for squamous cell carcinoma of the head and neck – Michael G. McCusker Jr. M.D. University …

Head and Neck 1 Min Read

Michael Gerard McCusker, MD – University of Maryland Medical Systems discusses Cisplatin every three weeks versus weekly cisplatin or carboplatin…

A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab – In Conclusion – Rodney Paul Rocconi MD University of South Alabama @…

Ovarian 1 Min Read

Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…

A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab – Common Questions – Rodney Paul Rocconi MD University of South Alabam…

Ovarian 1 Min Read

Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…

A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab Rodney Paul Rocconi MD University of South Alabama @UofSouthAlabama @r…

Ovarian 1 Min Read

Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy…

Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract 5020 – Abstract 5020 – Shilpa Gupta MD – Cleveland Clinic @CleClinicMD #bladder…

Bladder 1 Min Read

Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract…

Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract 5020 – Abstract 5019 – Shilpa Gupta MD – Cleveland Clinic @CleClinicMD #bladder…

Urology 1 Min Read

Shilpa Gupta, MD – Cleveland Clinic discusses Perioperative Novel Systemic Immunotherapy-Based Approaches in Urinary Cancers – Abstract 5019 and Abstract…

Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically – In Conclusion – Miguel Garcia-Guzman PH.D…

Head and Neck 1 Min Read

Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox…

Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically – Affect Clinicians – Miguel Garcia-Guzman …

Head and Neck 1 Min Read

Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox…

Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically – Common Questions – Miguel Garcia-Guzman P…

Head and Neck 1 Min Read

Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox…

Rakuten Medical Presents Data during AACR Characterizing how Illuminox Induces Cancer Cell Death and Enhances the Immune Response Preclinically – Miguel Garcia-Guzman PH.D. Rakuten Medica…

Head and Neck 1 Min Read

Miguel Garcia-Guzman, PH.D., Vice Chairman, Chief Scientific Officer, Rakuten Medical discusses Rakuten Medical Presents Data during AACR Characterizing how Illuminox…

Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry – In Conclusion – Anne Harris MHP Childrens Minnesota @childre…

Other 1 Min Read

Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…

Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry – Next Steps – Anne Harris MHP Childrens Minnesota @childrensm…

Other 1 Min Read

Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…

Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry – Will this affect clinicians today – Anne Harris MHP Children…

Other 1 Min Read

Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…

Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stJuvenile granulosa cell tumor: An interim report from the international ovarian and testic…

Other 1 Min Read

Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…

Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry – Anne Harris MHP Childrens Minnesota @childrensmn #juvenilegr…

Other 1 Min Read

Anne Harris, MHP Childrens Minnesota discusses Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal…

New Data on ALKS 4230 and The combination of a mouse ortholog of ALKS 4230 – In Closing – Heather Losey Ph.D. and Jared Lopes Ph.D. Alkermes @Alkermes #coloncancer

Colorectal 1 Min Read

Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…

New Data on ALKS 4230 and The combination of a mouse ortholog of ALKS 4230 – Common Questions – Heather Losey Ph.D. and Jared Lopes Ph.D. Alkermes @Alkermes #coloncancer

Colorectal 1 Min Read

Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…

New Data on ALKS 4230 and The combination of a mouse ortholog of ALKS 4230 – Heather Losey Ph.D. and Jared Lopes Ph.D. Alkermes @Alkermes #coloncancer

Colorectal 1 Min Read

Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia – Future of ClonoS…

Chronic Lymphocytic Leukemia 1 Min Read

John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia – Common Questions…

Chronic Lymphocytic Leukemia 1 Min Read

John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia – John Pagel, MD S…

Chronic Lymphocytic Leukemia 1 Min Read

John Pagel, MD Swedish Cancer Institute discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia – What do you think the future holds for the …

Chronic Lymphocytic Leukemia 1 Min Read

Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia – FDA clearance of clonoSEQ for CLL – Brian K…

Chronic Lymphocytic Leukemia 1 Min Read

Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…

Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD in Patients with Chronic Lymphocytic Leukemia – Brian Koffman MD CLL Society Inc. @CllSocie…

Chronic Lymphocytic Leukemia 1 Min Read

Brian Koffman, MD CLL Society Inc. discusses Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess MRD…

Previous 1 … 10 11 12 13 14 … 50 Next
Recent Posts
  • ESMO 2025 Top 10 Breast Cancer Abstracts: 10 Positive Breakthroughs
  • TCR-T Therapy: 49% Risk Cut & 39% Response
  • ESMO 2025 Top 10 Genitourinary Cancer Must-See Abstracts: 78% rPFS Boost Unveiled
  • Immune Checkpoint Inhibitors Myocarditis: 1% Risk, 50% Fatal – UCSF Insights
  • TIL Therapy Breakthroughs for Oncologists and Oncology Professionals
Connect With Us on Social
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
X (Twitter) LinkedIn Facebook YouTube
  • FDA
  • Conferences
    • AACR
    • ASBRS
    • ASCO
    • SABCS
    • ASH
    • ESMO
    • MOASC
    • Upcoming Oncology Conferences
  • Cancers
    • Breast Cancer
    • Prostate Cancer Treatment
    • Lung Cancer Treatment
    • Gastrointestinal Cancer Treatment
    • Melanoma Skin Cancer Treatment
    • Non-Hodgkin Lymphoma
    • Kidney
    • Acute Lymphoblastic Leukemia
    • Acute Myelogenous Leukemia
    • Bone Metastases
    • Brain
    • Business Management
    • Cervical
    • Chronic Lymphocytic Leukemia
    • Chronic Myelogenous Leukemia
    • Colorectal
    • COVID-19
    • General
    • Genitourinary
    • Head and Neck
    • Help
    • Hematologic Malignancies
    • Hodgkin Lymphoma
    • Imaging
    • Immunotherapy
    • Liver
    • Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Disease
    • News
    • Non-Small Cell Lung Cancer
    • Other
    • Ovarian
    • Pancreatic
    • Patient Resources
    • Pediatric
    • Sarcoma
    • Sickle Cell
    • Small Cell Lung Cancer
    • Supportive Care
    • Testicular
    • Urology
    • Uterine
  • About
  • Contact
  • Advertise
    • Advertising and Services – Media Kit 2025 – OncologyTube.com
    • Oncology Press Release Distribution
© 2025 Copyright Protected Medicus Networks, Inc. Privacy Policy

Type above and press Enter to search. Press Esc to cancel.